Kura Oncology Announces Issuance of U.S. Patent for Lead Product Candidate Tipifarnib in Head and Neck Cancer
July 18, 2017 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, July 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Establishes Collaboration with Foundation Medicine to Support Tipifarnib Development in HRAS Mutant Head and Neck Cancer
July 13, 2017 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, July 13, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Added to Russell 3000® Index
June 26, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Presents Preliminary Clinical and Preclinical Data for Tipifarnib in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
June 14, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Announces Data Presentations for Tipifarnib at the International Conference on Malignant Lymphoma and the European Hematology Association Annual Meeting
June 07, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., June 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology to Participate in Two Upcoming Investor Conferences
May 30, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports First Quarter 2017 Operational and Financial Results
May 15, 2017 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (NASDAQ:KURA) a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Report First Quarter 2017 Financial Results
May 08, 2017 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Granted U.S. Patent for Clinical-Stage ERK Inhibitor, KO-947
April 19, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., April 19, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947
April 07, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., April 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...